NASDAQ: LBRXLb Pharmaceuticals Inc Stock
$21.45+0.28 (+1.32%)
Updated Jan 30, 2026
LBRX Price
$21.45
Fair Value Price
$5.45
Market Cap
$542.67M
52 Week Low
$13.36
52 Week High
$24.46
P/E
N/A
P/B
1.75x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
N/A
Beta
0.28
Next Earnings
Feb 25, 2026
Ex-Dividend
N/A
Next Dividend
N/A
LBRX Overview
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LBRX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LBRX
Ranked#172 of 483
Ranked#172 of 483
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.58 | A | |
| $164.49 | A | |
| $20.47 | A |
Be the first to know about important LBRX news, forecast changes, insider trades & much more!
LBRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LBRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LBRX ($21.45) is overvalued by 293.89% relative to our estimate of its Fair Value price of $5.45 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LBRX ($21.45) is not significantly undervalued (293.89%) relative to our estimate of its Fair Value price of $5.45 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LBRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more LBRX due diligence checks available for Premium users.
Valuation
LBRX fair value
Fair Value of LBRX stock based on Discounted Cash Flow (DCF)
Price
$21.45
Fair Value
$5.45
Overvalued by
293.89%
LBRX ($21.45) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LBRX ($21.45) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LBRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.75x
Industry
5.44x
LBRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LBRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.6M
Profit Margin
0%
Assets to liabilities
Assets
$320.7M
Liabilities
$10.5M
Debt to equity
0.03
LBRX's short-term assets ($316.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LBRX's short-term assets ($316.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LBRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
-$44.8M
Financing
$303.7M
LBRX vs Biotech Stocks
Lb Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.